Subscribe Become an Author Sign Up Log In

2nd Annual Bispecifics in Discovery & Development Congress

   by BiopharmaTrend    180    Comments 0

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Oxford Global’s 2nd Annual Bispecifics in Discovery & Development Congress will be attended by over 450 visionary leaders to network about the latest developments & participate in presentations from the areas of engineering, bioanalysis, biotherapeutics and bispecifics.

New for 2020 is the introduction of the kick-off sessions, providing an interactive experience for delegates through roundtable & panel discussions.  

Key Speakers Include:  

  • Tristan Vaughan, Vice President, AstraZeneca 
  • John McCafferty, Chief Executive Officer, IONTAS Pharmaceuticals 
  • Surinder Kaur, Director, Genentech 
  • Kristin Brown, Director, GlaxoSmithKline 

 

VIEW AGENDA: https://bit.ly/30vvvXx

Part of the Biologics Series, it is co-located the 13th Annual Proteins & Antibodies Congress and the 7th Annual Peptides & Oligonucleotides Congress

2020 Live Webinar:

“Bispecific Antibodies Targeting The Innate Immune Checkpoint CD47

Presented by Nicolas Fischer, Chief Executive Officer, Light Chain Bioscience

Tuesday 21st January 2020 | 2PM UK GMT

REGISTER FOR FREE: https://bit.ly/2sAyHUM

Go Social: Join our Proteins Network on LinkedIn, follow us on Twitter at @biologicsconf and join the conversation using the hashtag #Biologics20

For more information about the event, please contact Bradley Copeman at b.copeman@oxfordglobal.co.uk or visit the website: https://bit.ly/2RlkT9v

 

Date: 27 - 29 April 2020

Location: London, UK

Share this:              

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *